Muutke küpsiste eelistusi

E-raamat: Hepatitis B and C: Management and Treatment

(Groupe Hospitalier Piti¿-Salp¿tri¿re, Paris, France)
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 25-Aug-2004
  • Kirjastus: CRC Press
  • Keel: eng
  • ISBN-13: 9781135410353
Teised raamatud teemal:
  • Formaat - EPUB+DRM
  • Hind: 54,59 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: EPUB+DRM
  • Ilmumisaeg: 25-Aug-2004
  • Kirjastus: CRC Press
  • Keel: eng
  • ISBN-13: 9781135410353
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment second edition provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effects, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side-effects to the patient.
Introduction vii
I HEPATITIS C
Natural history of hepatitis C: Epidemiology
3(4)
Natural history of hepatitis C: Hepatic manifestations
7(8)
Natural history of hepatitis C: Extrahepatic manifestations and quality of life
15(4)
Management protocols in chronic hepatitis C
19(16)
Management of relapsers and nonresponders---maintenance therapy
35(4)
Management of patients with cirrhosis
39(2)
Management of patients coinfected by HCV and HIV
41(2)
Management of HCV infection after liver transplantation
43(2)
Management of patients with renal disease
45(2)
Other difficult-to-treat populations
47(2)
Safety of interferon, pegylated interferon (PEG-IFN) and ribavirin
49(6)
Who needs to be treated and how to explain the goals to the patient
55(2)
What is the cost-effectiveness of combination regimes?
57(2)
Management of acute hepatitis C
59(2)
Practical guidelines for the management of hepatitis C
61(4)
New drugs in development
65(14)
References
69(10)
II HEPATITIS B
Natural history of hepatitis B: Epidemiology
79(4)
Natural history of hepatitis B: Hepatic manifestations
83(10)
Natural history of hepatitis B: Extrahepatic manifestations and quality of life
93(2)
Goal of treatment in chronic hepatitis B
95(2)
Efficacy of interferon and pegylated Interferon (PEG-IFN)
97(4)
Efficacy of lamivudine
101(6)
Comparison between lamivudine, interferon and the combination of interferon and lamlvudine
107(2)
Safety of lamivudine
109(2)
Efficacy of adefovir
111(4)
Safety of adefovir
115(2)
First-line treatment of chronic hepatitis B: Adefovir, lamivudine or Interferon?
117(2)
New drugs in development
119(2)
Who needs to be treated and how to explain the goals to the patient
121(4)
Management of relapsers and nonresponders
125(2)
Management of patients coinfected by HBV and HIV
127(2)
Management of transplanted patients chronically infected by HBV
129(2)
Cost-effectiveness of treatment
131(10)
References
133(8)
III BIOCHEMICAL MARKERS: AN ALTERNATIVE TO LIVER BIOPSIES
Needle biopsy of the liver: Values and limitations
141(10)
Advantage and limits of biochemical markers
151
References
157
Poynard, Thierry